Bionet (TWO:1784) — Stock Price
Bionet (TWO:1784) is currently trading at NT$61.80 TWD, up 2.66% today. Over the past 52 weeks, shares have ranged between NT$56.10 and NT$115.50. This page tracks Bionet's live share price on the TWO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 1784 market cap.
Bionet (1784) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Bionet's daily closing share price and trading volume on the TWO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Bionet Income Statement — Revenue, Profit & Earnings by Year
Bionet's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | NT$1.24 Billion | NT$1.22 Billion | NT$1.13 Billion | NT$980.38 Million | NT$921.42 Million |
| Cost of Revenue | NT$552.72 Million | NT$536.26 Million | NT$489.03 Million | NT$438.16 Million | NT$418.35 Million |
| Gross Profit | NT$683.87 Million | NT$685.77 Million | NT$638.28 Million | NT$542.22 Million | NT$503.07 Million |
| Research & Development | NT$150.78 Million | NT$139.02 Million | NT$118.75 Million | NT$90.30 Million | NT$85.57 Million |
| SG&A | NT$545.20 Million | NT$483.75 Million | NT$137.68 Million | NT$129.11 Million | NT$139.89 Million |
| Total Operating Expenses | NT$1.25 Billion | NT$1.16 Billion | NT$551.98 Million | NT$482.25 Million | NT$471.54 Million |
| Operating Income | NT$-12.11 Million | NT$63.00 Million | NT$109.10 Million | NT$74.05 Million | NT$41.91 Million |
| EBITDA | — | — | NT$148.70 Million | NT$117.10 Million | NT$80.74 Million |
| EBIT | — | — | NT$109.10 Million | NT$74.05 Million | NT$41.91 Million |
| Interest Expense | NT$1.50 Million | NT$1.28 Million | NT$410.00K | NT$458.00K | NT$389.00K |
| Income Before Tax | NT$19.27 Million | NT$102.24 Million | NT$107.08 Million | NT$70.46 Million | NT$41.19 Million |
| Income Tax Expense | — | — | NT$25.69 Million | NT$16.86 Million | NT$8.55 Million |
| Net Income | NT$51.43 Million | NT$83.70 Million | NT$78.40 Million | NT$37.97 Million | NT$26.62 Million |
Bionet Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Bionet's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | NT$3.08 Billion | NT$3.16 Billion | NT$2.35 Billion | NT$1.84 Billion | NT$1.78 Billion |
| Total Current Assets | NT$1.87 Billion | NT$2.00 Billion | NT$1.27 Billion | NT$747.99 Million | NT$685.69 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | NT$1.14 Billion | NT$1.33 Billion | NT$668.86 Million | NT$277.20 Million | NT$263.29 Million |
| Net Receivables | NT$265.19 Million | NT$279.97 Million | NT$304.45 Million | NT$260.73 Million | NT$220.54 Million |
| Inventory | NT$125.85 Million | NT$81.34 Million | NT$55.54 Million | NT$46.70 Million | NT$79.34 Million |
| Property, Plant & Equipment | — | — | — | — | NT$515.20 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | NT$822.58 Million | NT$760.40 Million | NT$626.47 Million | NT$513.97 Million | NT$468.19 Million |
| Total Current Liabilities | NT$405.07 Million | NT$395.01 Million | NT$324.92 Million | NT$244.30 Million | NT$247.66 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | NT$-193.48 Million | NT$-146.37 Million | NT$-107.28 Million |
| Total Stockholder Equity | NT$1.27 Billion | NT$1.33 Billion | NT$1.19 Billion | NT$1.08 Billion | NT$1.10 Billion |
| Retained Earnings | NT$51.86 Million | NT$84.31 Million | NT$77.71 Million | NT$37.80 Million | NT$26.52 Million |
Bionet Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Bionet generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | NT$148.04 Million | NT$176.49 Million | NT$153.09 Million | NT$94.65 Million | NT$13.88 Million |
| Capital Expenditures | NT$132.18 Million | NT$103.49 Million | NT$26.28 Million | NT$32.91 Million | NT$16.66 Million |
| Free Cash Flow | NT$15.86 Million | NT$73.00 Million | NT$126.81 Million | NT$61.74 Million | NT$-2.79 Million |
| Investing Cash Flow | — | — | — | — | NT$-4.59 Million |
| Financing Cash Flow | — | — | NT$333.98 Million | NT$-51.90 Million | NT$-15.60 Million |
| Dividends Paid | NT$70.06 Million | NT$33.15 Million | NT$32.63 Million | NT$23.52 Million | NT$8.77 Million |
| Stock-Based Compensation | NT$24.42 Million | NT$26.25 Million | NT$4.99 Million | NT$0.00 | NT$2.44 Million |
| Depreciation | NT$62.33 Million | NT$45.57 Million | NT$39.60 Million | NT$43.05 Million | NT$38.84 Million |
| Change in Cash | NT$13.26 Million | NT$4.30 Million | NT$76.88 Million | NT$39.82 Million | NT$-6.56 Million |
Bionet Earnings History — EPS Actual vs. Analyst Estimates
Track Bionet's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 19, 2025 | — | — | — |
| May 31, 2023 | 0.49 | — | — |
| Mar 01, 2023 | 0.22 | — | — |
| Nov 30, 2022 | 0.34 | — | — |
| Aug 31, 2022 | 0.15 | — | — |
| Jun 01, 2022 | 0.10 | — | — |
| Mar 02, 2022 | -0.05 | — | — |
| Dec 01, 2021 | 0.11 | — | — |